Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study
Jones, M. W., Zhang, C., Oettel, K. R., Blank, J. H., Robinson, E. G., Ahuja, H. G., Kirschling, R. J., Johnson, P. H., Huie, M. S., Kolesar, J., Wims, M. B., Hernan, H., Campbell, T. C., Traynor, A. M., Hoang, T.
Published in Journal of clinical oncology (20.05.2011)
Published in Journal of clinical oncology (20.05.2011)
Get full text
Journal Article